Painful boney metastases.
Up to 90% of patients with metastatic or advanced stage cancer will experience significant cancer-related pain. Approximately half or more of patients diagnosed with cancer may experience bone pain. It has been estimated that tumor metastases to the skeleton affects roughly 400,000 US citizens annually. Carcinoma from breast, lung, and prostate cancers account for approximately 80% of secondary metastatic bone disease. Bone metastases may cause devastating clinical complications associated with dramatic reductions in quality of life, mobility, and independence, as well as excruciating refractory pain. Associated complications from osseous metastases also present a substantial economic burden. Currently, there are still a significantly high number of patients suffering with unrelieved pain from osseous metastases. Treatments for painful osseous metastases may not only diminish pain but also may improve quality of life and independence/mobility, and reduce skeletal morbidity, potential pathologic fractures, spinal cord compression, and other "skeletal-related events." Treatment strategies for painful osseous metastases include the following: systemic analgesics, intrathecal analgesics, glucocorticoids, radiation (external beam radiation, radiopharmaceuticals), ablative techniques (radiofrequency ablation and cryoablation), bisphosphonates, chemotherapeutic agents, inhibitors of RANKL-RANK interaction (eg, denosumab), hormonal therapies, interventional techniques (eg, kyphoplasty), and surgical approaches. Although the mechanisms underlying the development of bone metastases remain incompletely understood, there appears to be important bi-directional interactions between the tumor and the bone microenvironment. A greater understanding of the pathophysiology of painful osseous metastases may lead to better and more selective targeted analgesic therapy. Additionally, potential future therapeutic approaches to painful osseous metastases may revolutionize approaches to analgesia for this condition, leading to optimal outcomes with maximal pain relief and minimal adverse effects.
1Department of Anesthesiology, Albany Medical College, Albany, NY; Departments of2Anesthesiology 3Family Medicine, and 4Pharmacology, Rush University Medical College, Chicago, IL; 5Department of Anesthesiology, Northshore University Health System, Evanston, IL; and 6Skokie Hospital Pain Centers, Skokie, IL.
Howard S
HS
Smith
Robert L
RL
Barkin
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001859:Bone Neoplasms / Q000150:complications / Q000473:pathology* / Q000556:secondary; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000473:pathology; D010146:Pain / Q000209:etiology*; D059408:Pain Management / Q000379:methods*; D011788:Quality of Life; D059016:Tumor Microenvironment
D000700:Analgesics